MedPath

Clinical Investigation on differences in the magnitude of CRT response in WOmen versus ME

Phase 4
Completed
Conditions
Heart Failure: decreased pump function of the heart
10019280
Registration Number
NL-OMON55752
Lead Sponsor
Biotronik
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
94
Inclusion Criteria

indication for a de novo implantation of a CRT device according to ESC
Guidelines
written informed consent

Exclusion Criteria

CRT replacements or upgrades
Permanent Atrial Fibrilation
age < 18
NYHA IV
life expectancy less than 12 months

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Information on the heart function and volumes as measured with standard<br /><br>echocardiography: ejection fraction (%EF), volumes etc...</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>classification of HF status: NYHA I, II, III or IV<br /><br>QOL test: Minesotta Living with Heart Failure Questionaire<br /><br>exercise capacity test: 6 minute hall walk test<br /><br>SAE reporting with focus on HF hospitalization, mortality..<br /><br>composite HF score (modified Packer score)<br /><br>basline ECG (QRS duration and morphology) as predictor for CRT response (males<br /><br>vs females)</p><br>
© Copyright 2025. All Rights Reserved by MedPath